ID   S22A2_HUMAN             Reviewed;         555 AA.
AC   O15244; Q5T7Q6; Q6PIQ8; Q8NG62; Q9NQB9;
DT   26-FEB-2008, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 2.
DT   10-MAY-2017, entry version 149.
DE   RecName: Full=Solute carrier family 22 member 2;
DE   AltName: Full=Organic cation transporter 2;
DE            Short=hOCT2;
GN   Name=SLC22A2; Synonyms=OCT2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, FUNCTION,
RP   AND VARIANT ALA-270.
RC   TISSUE=Kidney cortex;
RX   PubMed=9260930; DOI=10.1089/dna.1997.16.871;
RA   Gorboulev V., Ulzheimer J.C., Akhoundova A., Ulzheimer-Teuber I.,
RA   Karbach U., Quester S., Baumann C., Lang F., Busch A.E., Koepsell H.;
RT   "Cloning and characterization of two human polyspecific organic cation
RT   transporters.";
RL   DNA Cell Biol. 16:871-881(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND VARIANT ALA-270.
RC   TISSUE=Kidney;
RX   PubMed=12089365; DOI=10.1097/01.ASN.0000019413.78751.46;
RA   Urakami Y., Akazawa M., Saito H., Okuda M., Inui K.;
RT   "cDNA cloning, functional characterization, and tissue distribution of
RT   an alternatively spliced variant of organic cation transporter hOCT2
RT   predominantly expressed in the human kidney.";
RL   J. Am. Soc. Nephrol. 13:1703-1710(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-270.
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   ALA-270.
RC   TISSUE=Colon, and Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-138.
RX   PubMed=10942111; DOI=10.1007/s004390000309;
RA   Gruendemann D., Schoemig E.;
RT   "Gene structures of the human non-neuronal monoamine transporters EMT
RT   and OCT2.";
RL   Hum. Genet. 106:627-635(2000).
RN   [8]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.
RX   PubMed=9687576;
RA   Busch A.E., Karbach U., Miska D., Gorboulev V., Akhoundova A.,
RA   Volk C., Arndt P., Ulzheimer J.C., Sonders M.S., Baumann C.,
RA   Waldegger S., Lang F., Koepsell H.;
RT   "Human neurons express the polyspecific cation transporter hOCT2,
RT   which translocates monoamine neurotransmitters, amantadine, and
RT   memantine.";
RL   Mol. Pharmacol. 54:342-352(1998).
RN   [9]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11758759; DOI=10.1023/A:1013070128668;
RA   Urakami Y., Okuda M., Masuda S., Akazawa M., Saito H., Inui K.;
RT   "Distinct characteristics of organic cation transporters, OCT1 and
RT   OCT2, in the basolateral membrane of renal tubules.";
RL   Pharm. Res. 18:1528-1534(2001).
RN   [10]
RP   TISSUE SPECIFICITY.
RX   PubMed=11912245;
RA   Motohashi H., Sakurai Y., Saito H., Masuda S., Urakami Y., Goto M.,
RA   Fukatsu A., Ogawa O., Inui K.;
RT   "Gene expression levels and immunolocalization of organic ion
RT   transporters in the human kidney.";
RL   J. Am. Soc. Nephrol. 13:866-874(2002).
RN   [11]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=12538837; DOI=10.1124/jpet.102.044404;
RA   Grundemann D., Hahne C., Berkels R., Schomig E.;
RT   "Agmatine is efficiently transported by non-neuronal monoamine
RT   transporters extraneuronal monoamine transporter (EMT) and organic
RT   cation transporter 2 (OCT2).";
RL   J. Pharmacol. Exp. Ther. 304:810-817(2003).
RN   [12]
RP   FUNCTION.
RX   PubMed=15496291; DOI=10.1016/j.ejphar.2004.09.032;
RA   Motohashi H., Uwai Y., Hiramoto K., Okuda M., Inui K.;
RT   "Different transport properties between famotidine and cimetidine by
RT   human renal organic ion transporters (SLC22A).";
RL   Eur. J. Pharmacol. 503:25-30(2004).
RN   [13]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=16314463; DOI=10.1016/S0002-9440(10)61234-5;
RA   Ciarimboli G., Ludwig T., Lang D., Pavenstaedt H., Koepsell H.,
RA   Piechota H.J., Haier J., Jaehde U., Zisowsky J., Schlatter E.;
RT   "Cisplatin nephrotoxicity is critically mediated via the human organic
RT   cation transporter 2.";
RL   Am. J. Pathol. 167:1477-1484(2005).
RN   [14]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16272756; DOI=10.2133/dmpk.20.379;
RA   Kimura N., Masuda S., Tanihara Y., Ueo H., Okuda M., Katsura T.,
RA   Inui K.;
RT   "Metformin is a superior substrate for renal organic cation
RT   transporter OCT2 rather than hepatic OCT1.";
RL   Drug Metab. Pharmacokinet. 20:379-386(2005).
RN   [15]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16006492; DOI=10.1124/jpet.105.088104;
RA   Tahara H., Kusuhara H., Endou H., Koepsell H., Imaoka T., Fuse E.,
RA   Sugiyama Y.;
RT   "A species difference in the transport activities of H2 receptor
RT   antagonists by rat and human renal organic anion and cation
RT   transporters.";
RL   J. Pharmacol. Exp. Ther. 315:337-345(2005).
RN   [16]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15783073; DOI=10.1007/s11095-004-1193-3;
RA   Kimura N., Okuda M., Inui K.;
RT   "Metformin transport by renal basolateral organic cation transporter
RT   hOCT2.";
RL   Pharm. Res. 22:255-259(2005).
RN   [17]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16394027; DOI=10.1152/ajpcell.00622.2005;
RA   Biermann J., Lang D., Gorboulev V., Koepsell H., Sindic A.,
RA   Schroter R., Zvirbliene A., Pavenstadt H., Schlatter E.,
RA   Ciarimboli G.;
RT   "Characterization of regulatory mechanisms and states of human organic
RT   cation transporter 2.";
RL   Am. J. Physiol. 290:C1521-C1531(2006).
RN   [18]
RP   FUNCTION.
RX   PubMed=16951202; DOI=10.1158/0008-5472.CAN-06-0769;
RA   Zhang S., Lovejoy K.S., Shima J.E., Lagpacan L.L., Shu Y., Lapuk A.,
RA   Chen Y., Komori T., Gray J.W., Chen X., Lippard S.J., Giacomini K.M.;
RT   "Organic cation transporters are determinants of oxaliplatin
RT   cytotoxicity.";
RL   Cancer Res. 66:8847-8857(2006).
RN   [19]
RP   FUNCTION.
RX   PubMed=17072098; DOI=10.2133/dmpk.21.432;
RA   Okuda M., Kimura N., Inui K.;
RT   "Interactions of fluoroquinolone antibacterials, DX-619 and
RT   levofloxacin, with creatinine transport by renal organic cation
RT   transporter hOCT2.";
RL   Drug Metab. Pharmacokinet. 21:432-436(2006).
RN   [20]
RP   FUNCTION.
RX   PubMed=16914559; DOI=10.1124/jpet.106.110346;
RA   Yonezawa A., Masuda S., Yokoo S., Katsura T., Inui K.;
RT   "Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are
RT   substrates for human organic cation transporters (SLC22A1-3 and
RT   multidrug and toxin extrusion family).";
RL   J. Pharmacol. Exp. Ther. 319:879-886(2006).
RN   [21]
RP   FUNCTION.
RX   PubMed=17582384; DOI=10.1016/j.bcp.2007.03.004;
RA   Yokoo S., Yonezawa A., Masuda S., Fukatsu A., Katsura T., Inui K.;
RT   "Differential contribution of organic cation transporters, OCT2 and
RT   MATE1, in platinum agent-induced nephrotoxicity.";
RL   Biochem. Pharmacol. 74:477-487(2007).
RN   [22]
RP   TISSUE SPECIFICITY.
RX   PubMed=17393420; DOI=10.1002/mrd.20697;
RA   Bottalico B., Noskova V., Pilka R., Larsson I., Domanski H.,
RA   Casslen B., Hansson S.R.;
RT   "The organic cation transporters (OCT1, OCT2, EMT) and the plasma
RT   membrane monoamine transporter (PMAT) show differential distribution
RT   and cyclic expression pattern in human endometrium and early pregnancy
RT   decidua.";
RL   Mol. Reprod. Dev. 74:1303-1311(2007).
RN   [23]
RP   VARIANT SER-54, AND CHARACTERIZATION OF VARIANTS ILE-165; ALA-270;
RP   CYS-400 AND GLN-432.
RX   PubMed=12142729; DOI=10.1097/00008571-200207000-00007;
RA   Leabman M.K., Huang C.C., Kawamoto M., Johns S.J., Stryke D.,
RA   Ferrin T.E., DeYoung J., Taylor T., Clark A.G., Herskowitz I.,
RA   Giacomini K.M.;
RT   "Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit
RT   altered function.";
RL   Pharmacogenetics 12:395-405(2002).
RN   [24]
RP   VARIANTS MET-201 AND ALA-270.
RX   PubMed=17111267; DOI=10.1007/s10038-006-0087-0;
RA   Shikata E., Yamamoto R., Takane H., Shigemasa C., Ikeda T., Otsubo K.,
RA   Ieiri I.;
RT   "Human organic cation transporter (OCT1 and OCT2) gene polymorphisms
RT   and therapeutic effects of metformin.";
RL   J. Hum. Genet. 52:117-122(2007).
CC   -!- FUNCTION: Mediates tubular uptake of organic compounds from
CC       circulation. Mediates the influx of agmatine, dopamine,
CC       noradrenaline (norepinephrine), serotonin, choline, famotidine,
CC       ranitidine, histamin, creatinine, amantadine, memantine,
CC       acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP,
CC       amiloride, metformin, N-1-methylnicotinamide (NMN),
CC       tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP),
CC       cimetidine, cisplatin and oxaliplatin. Cisplatin may develop a
CC       nephrotoxic action. Transport of creatinine is inhibited by
CC       fluoroquinolones such as DX-619 and LVFX. This transporter is a
CC       major determinant of the anticancer activity of oxaliplatin and
CC       may contribute to antitumor specificity.
CC       {ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC       ECO:0000269|PubMed:15496291, ECO:0000269|PubMed:15783073,
CC       ECO:0000269|PubMed:16006492, ECO:0000269|PubMed:16272756,
CC       ECO:0000269|PubMed:16314463, ECO:0000269|PubMed:16394027,
CC       ECO:0000269|PubMed:16914559, ECO:0000269|PubMed:16951202,
CC       ECO:0000269|PubMed:17072098, ECO:0000269|PubMed:17582384,
CC       ECO:0000269|PubMed:9260930, ECO:0000269|PubMed:9687576}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1 mM for agmatine {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=95 uM for amiloride {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=24 uM for ASP {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=34 uM for memantine {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=27 uM for amantadine {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=1.38 mM for metformin {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=1.9 mM for noradrenaline {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=1.9 mM for norepinephrine {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=1.3 mM for histamine {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=0.39 mM for dopamine {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=0.08 mM for serotonine {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=72.6 uM for cimetidine (at pH 7.4 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:11758759, ECO:0000269|PubMed:12089365,
CC         ECO:0000269|PubMed:12538837, ECO:0000269|PubMed:15783073,
CC         ECO:0000269|PubMed:16006492, ECO:0000269|PubMed:16272756,
CC         ECO:0000269|PubMed:16394027, ECO:0000269|PubMed:9687576};
CC         KM=56.1 uM for famotidine {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=65.2 uM for ranitidine {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=431 uM for TEA (isoform 1) {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         KM=63 uM for TEA (isoform 2) {ECO:0000269|PubMed:11758759,
CC         ECO:0000269|PubMed:12089365, ECO:0000269|PubMed:12538837,
CC         ECO:0000269|PubMed:15783073, ECO:0000269|PubMed:16006492,
CC         ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16394027,
CC         ECO:0000269|PubMed:9687576};
CC         Vmax=3770 pmol/min/mg enzyme for TEA uptake (isoform 1)
CC         {ECO:0000269|PubMed:11758759, ECO:0000269|PubMed:12089365,
CC         ECO:0000269|PubMed:12538837, ECO:0000269|PubMed:15783073,
CC         ECO:0000269|PubMed:16006492, ECO:0000269|PubMed:16272756,
CC         ECO:0000269|PubMed:16394027, ECO:0000269|PubMed:9687576};
CC         Vmax=314 pmol/min/mg enzyme for TEA uptake (isoform 2)
CC         {ECO:0000269|PubMed:11758759, ECO:0000269|PubMed:12089365,
CC         ECO:0000269|PubMed:12538837, ECO:0000269|PubMed:15783073,
CC         ECO:0000269|PubMed:16006492, ECO:0000269|PubMed:16272756,
CC         ECO:0000269|PubMed:16394027, ECO:0000269|PubMed:9687576};
CC         Vmax=11.9 nmol/min/mg enzyme for metformin uptake
CC         {ECO:0000269|PubMed:11758759, ECO:0000269|PubMed:12089365,
CC         ECO:0000269|PubMed:12538837, ECO:0000269|PubMed:15783073,
CC         ECO:0000269|PubMed:16006492, ECO:0000269|PubMed:16272756,
CC         ECO:0000269|PubMed:16394027, ECO:0000269|PubMed:9687576};
CC         Vmax=2170 pmol/min/mg enzyme for cimetidine uptake
CC         {ECO:0000269|PubMed:11758759, ECO:0000269|PubMed:12089365,
CC         ECO:0000269|PubMed:12538837, ECO:0000269|PubMed:15783073,
CC         ECO:0000269|PubMed:16006492, ECO:0000269|PubMed:16272756,
CC         ECO:0000269|PubMed:16394027, ECO:0000269|PubMed:9687576};
CC         Vmax=204 pmol/min/mg enzyme for famotidine uptake
CC         {ECO:0000269|PubMed:11758759, ECO:0000269|PubMed:12089365,
CC         ECO:0000269|PubMed:12538837, ECO:0000269|PubMed:15783073,
CC         ECO:0000269|PubMed:16006492, ECO:0000269|PubMed:16272756,
CC         ECO:0000269|PubMed:16394027, ECO:0000269|PubMed:9687576};
CC         Vmax=265 pmol/min/mg enzyme for ranitidine uptake
CC         {ECO:0000269|PubMed:11758759, ECO:0000269|PubMed:12089365,
CC         ECO:0000269|PubMed:12538837, ECO:0000269|PubMed:15783073,
CC         ECO:0000269|PubMed:16006492, ECO:0000269|PubMed:16272756,
CC         ECO:0000269|PubMed:16394027, ECO:0000269|PubMed:9687576};
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O15244-1; Sequence=Displayed;
CC       Name=2; Synonyms=OCT2-A;
CC         IsoId=O15244-2; Sequence=VSP_031773, VSP_031774;
CC       Name=3;
CC         IsoId=O15244-3; Sequence=VSP_031771, VSP_031772;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Mainly expressed in kidney. Localized at the
CC       luminal membrane and basolateral membrane of kidney distal tubule
CC       and proximal tubules. To a lower extent, expressed in neurons of
CC       the cerebral cortex and in various subcortical nuclei (at protein
CC       levels). Also detected in secretory phase endometrium; in
CC       scattered cells in the stroma. {ECO:0000269|PubMed:11912245,
CC       ECO:0000269|PubMed:17393420, ECO:0000269|PubMed:9260930,
CC       ECO:0000269|PubMed:9687576}.
CC   -!- INDUCTION: May be down-regulated in diabetic patients.
CC       {ECO:0000269|PubMed:16314463}.
CC   -!- SIMILARITY: Belongs to the major facilitator (TC 2.A.1)
CC       superfamily. Organic cation transporter (TC 2.A.1.19) family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X98333; CAA66978.1; -; mRNA.
DR   EMBL; AB075951; BAC02720.1; -; mRNA.
DR   EMBL; AK290787; BAF83476.1; -; mRNA.
DR   EMBL; AL162582; CAI20003.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW47602.1; -; Genomic_DNA.
DR   EMBL; BC030978; AAH30978.1; -; mRNA.
DR   EMBL; BC039899; AAH39899.1; -; mRNA.
DR   EMBL; AJ251885; CAB96133.1; -; Genomic_DNA.
DR   CCDS; CCDS5276.1; -. [O15244-1]
DR   RefSeq; NP_003049.2; NM_003058.3. [O15244-1]
DR   UniGene; Hs.436385; -.
DR   ProteinModelPortal; O15244; -.
DR   BioGrid; 112469; 8.
DR   IntAct; O15244; 8.
DR   STRING; 9606.ENSP00000355920; -.
DR   BindingDB; O15244; -.
DR   ChEMBL; CHEMBL1743122; -.
DR   DrugBank; DB08838; Agmatine.
DR   DrugBank; DB00915; Amantadine.
DR   DrugBank; DB00594; Amiloride.
DR   DrugBank; DB02533; Aminoguanidine.
DR   DrugBank; DB00345; Aminohippuric acid.
DR   DrugBank; DB01114; Chlorphenamine.
DR   DrugBank; DB00122; Choline.
DR   DrugBank; DB00501; Cimetidine.
DR   DrugBank; DB00515; Cisplatin.
DR   DrugBank; DB00242; Cladribine.
DR   DrugBank; DB00907; Cocaine.
DR   DrugBank; DB00987; Cytarabine.
DR   DrugBank; DB00694; Daunorubicin.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB01160; Dinoprost Tromethamine.
DR   DrugBank; DB00917; Dinoprostone.
DR   DrugBank; DB01075; Diphenhydramine.
DR   DrugBank; DB00280; Disopyramide.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB00668; Epinephrine.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB00927; Famotidine.
DR   DrugBank; DB00690; Flurazepam.
DR   DrugBank; DB00365; Grepafloxacin.
DR   DrugBank; DB00536; Guanidine.
DR   DrugBank; DB00667; Histamine Phosphate.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB00709; Lamivudine.
DR   DrugBank; DB01137; Levofloxacin.
DR   DrugBank; DB01043; Memantine.
DR   DrugBank; DB00331; Metformin.
DR   DrugBank; DB00264; Metoprolol.
DR   DrugBank; DB00184; Nicotine.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB00526; Oxaliplatin.
DR   DrugBank; DB01580; Oxprenolol.
DR   DrugBank; DB01337; Pancuronium.
DR   DrugBank; DB00914; Phenformin.
DR   DrugBank; DB00925; Phenoxybenzamine.
DR   DrugBank; DB00413; Pramipexole.
DR   DrugBank; DB00457; Prazosin.
DR   DrugBank; DB01032; Probenecid.
DR   DrugBank; DB01035; Procainamide.
DR   DrugBank; DB00396; Progesterone.
DR   DrugBank; DB00571; Propranolol.
DR   DrugBank; DB01103; Quinacrine.
DR   DrugBank; DB00908; Quinidine.
DR   DrugBank; DB00468; Quinine.
DR   DrugBank; DB00206; Reserpine.
DR   DrugBank; DB08837; Tetraethylammonium.
DR   DrugBank; DB00152; Thiamine.
DR   DrugBank; DB01199; Tubocurarine.
DR   DrugBank; DB00570; Vinblastine.
DR   DrugBank; DB00495; Zidovudine.
DR   GuidetoPHARMACOLOGY; 1020; -.
DR   TCDB; 2.A.1.19.30; the major facilitator superfamily (mfs).
DR   iPTMnet; O15244; -.
DR   PhosphoSitePlus; O15244; -.
DR   BioMuta; SLC22A2; -.
DR   PaxDb; O15244; -.
DR   PeptideAtlas; O15244; -.
DR   PRIDE; O15244; -.
DR   Ensembl; ENST00000366953; ENSP00000355920; ENSG00000112499. [O15244-1]
DR   GeneID; 6582; -.
DR   KEGG; hsa:6582; -.
DR   UCSC; uc003qtf.4; human. [O15244-1]
DR   CTD; 6582; -.
DR   DisGeNET; 6582; -.
DR   GeneCards; SLC22A2; -.
DR   H-InvDB; HIX0025014; -.
DR   HGNC; HGNC:10966; SLC22A2.
DR   HPA; CAB068236; -.
DR   HPA; CAB068237; -.
DR   HPA; HPA008567; -.
DR   MIM; 602608; gene.
DR   neXtProt; NX_O15244; -.
DR   OpenTargets; ENSG00000112499; -.
DR   PharmGKB; PA331; -.
DR   eggNOG; KOG0255; Eukaryota.
DR   eggNOG; COG0477; LUCA.
DR   GeneTree; ENSGT00760000118852; -.
DR   HOGENOM; HOG000234568; -.
DR   HOVERGEN; HBG061545; -.
DR   InParanoid; O15244; -.
DR   KO; K08199; -.
DR   OMA; PWAASNM; -.
DR   OrthoDB; EOG091G05AC; -.
DR   PhylomeDB; O15244; -.
DR   TreeFam; TF315847; -.
DR   Reactome; R-HSA-112311; Neurotransmitter Clearance In The Synaptic Cleft.
DR   Reactome; R-HSA-181430; Norepinephrine Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-2161517; Abacavir transmembrane transport.
DR   Reactome; R-HSA-442660; Na+/Cl- dependent neurotransmitter transporters.
DR   Reactome; R-HSA-549127; Organic cation transport.
DR   GeneWiki; SLC22A2; -.
DR   GenomeRNAi; 6582; -.
DR   PRO; PR:O15244; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000112499; -.
DR   CleanEx; HS_SLC22A2; -.
DR   ExpressionAtlas; O15244; baseline and differential.
DR   Genevisible; O15244; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0005277; F:acetylcholine transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0005329; F:dopamine transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0005326; F:neurotransmitter transporter activity; TAS:Reactome.
DR   GO; GO:0005333; F:norepinephrine transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0008514; F:organic anion transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015101; F:organic cation transmembrane transporter activity; IDA:MGI.
DR   GO; GO:0015651; F:quaternary ammonium group transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0008513; F:secondary active organic cation transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0007589; P:body fluid secretion; TAS:ProtInc.
DR   GO; GO:0015872; P:dopamine transport; IBA:GO_Central.
DR   GO; GO:0006855; P:drug transmembrane transport; TAS:Reactome.
DR   GO; GO:0042136; P:neurotransmitter biosynthetic process; TAS:Reactome.
DR   GO; GO:0007269; P:neurotransmitter secretion; TAS:Reactome.
DR   GO; GO:0006836; P:neurotransmitter transport; IBA:GO_Central.
DR   GO; GO:0015874; P:norepinephrine transport; IBA:GO_Central.
DR   GO; GO:0015695; P:organic cation transport; IDA:MGI.
DR   CDD; cd06174; MFS; 1.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR005828; MFS_sugar_transport-like.
DR   InterPro; IPR004749; Orgcat_transp/SVOP.
DR   InterPro; IPR005829; Sugar_transporter_CS.
DR   Pfam; PF00083; Sugar_tr; 1.
DR   SUPFAM; SSF103473; SSF103473; 1.
DR   TIGRFAMs; TIGR00898; 2A0119; 1.
DR   PROSITE; PS50850; MFS; 1.
DR   PROSITE; PS00216; SUGAR_TRANSPORT_1; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Glycoprotein; Ion transport;
KW   Membrane; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN         1    555       Solute carrier family 22 member 2.
FT                                /FTId=PRO_0000320957.
FT   TOPO_DOM      1     22       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     23     43       Helical. {ECO:0000255}.
FT   TOPO_DOM     44    150       Extracellular. {ECO:0000255}.
FT   TRANSMEM    151    171       Helical. {ECO:0000255}.
FT   TOPO_DOM    172    177       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    178    198       Helical. {ECO:0000255}.
FT   TOPO_DOM    199    208       Extracellular. {ECO:0000255}.
FT   TRANSMEM    209    229       Helical. {ECO:0000255}.
FT   TOPO_DOM    230    238       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    239    259       Helical. {ECO:0000255}.
FT   TOPO_DOM    260    263       Extracellular. {ECO:0000255}.
FT   TRANSMEM    264    284       Helical. {ECO:0000255}.
FT   TOPO_DOM    285    348       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    349    369       Helical. {ECO:0000255}.
FT   TOPO_DOM    370    375       Extracellular. {ECO:0000255}.
FT   TRANSMEM    376    396       Helical. {ECO:0000255}.
FT   TOPO_DOM    397    414       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    415    435       Helical. {ECO:0000255}.
FT   TOPO_DOM    436    441       Extracellular. {ECO:0000255}.
FT   TRANSMEM    442    462       Helical. {ECO:0000255}.
FT   TOPO_DOM    463    464       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    465    485       Helical. {ECO:0000255}.
FT   TOPO_DOM    486    494       Extracellular. {ECO:0000255}.
FT   TRANSMEM    495    515       Helical. {ECO:0000255}.
FT   TOPO_DOM    516    555       Cytoplasmic. {ECO:0000255}.
FT   SITE        451    451       Involved in recognition of organic
FT                                cations and participates in structural
FT                                changes that occur during translocation
FT                                of organic cations. {ECO:0000250}.
FT   CARBOHYD     72     72       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ     225    242       ITEFVGRRYRRTVGIFYQ -> SKNVCACNCENKATSLPK
FT                                (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_031771.
FT   VAR_SEQ     243    555       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_031772.
FT   VAR_SEQ     427    483       DLQWLKIIISCLGRMGITMAYEIVCLVNAELYPTFIRNLGV
FT                                HICSSMCDIGGIITPF -> GKFQVKLESYLQDPGERECHG
FT                                PLIGKPCNLSSKSIWKDKLEGSIWDPSEQIHMASLL (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:12089365}.
FT                                /FTId=VSP_031773.
FT   VAR_SEQ     484    555       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12089365}.
FT                                /FTId=VSP_031774.
FT   VARIANT      54     54       P -> S (in dbSNP:rs8177504).
FT                                {ECO:0000269|PubMed:12142729}.
FT                                /FTId=VAR_039322.
FT   VARIANT     165    165       M -> I (lower Vmax; dbSNP:rs8177507).
FT                                {ECO:0000269|PubMed:12142729}.
FT                                /FTId=VAR_039323.
FT   VARIANT     201    201       T -> M (in dbSNP:rs145450955).
FT                                {ECO:0000269|PubMed:17111267}.
FT                                /FTId=VAR_039324.
FT   VARIANT     270    270       S -> A (increased Ki value for TBA
FT                                inhibition of MPP; dbSNP:rs316019).
FT                                {ECO:0000269|PubMed:12089365,
FT                                ECO:0000269|PubMed:12142729,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17111267,
FT                                ECO:0000269|PubMed:9260930}.
FT                                /FTId=VAR_039325.
FT   VARIANT     297    297       A -> G (in dbSNP:rs8177513).
FT                                /FTId=VAR_039326.
FT   VARIANT     400    400       R -> C (lower Vmax and reduced Ki value
FT                                for TBA inhibition of MPP;
FT                                dbSNP:rs8177516).
FT                                {ECO:0000269|PubMed:12142729}.
FT                                /FTId=VAR_039327.
FT   VARIANT     432    432       K -> Q (lower Km value for MPP and
FT                                reduced Ki value for TBA inhibition of
FT                                MPP; dbSNP:rs8177517).
FT                                {ECO:0000269|PubMed:12142729}.
FT                                /FTId=VAR_039328.
FT   VARIANT     463    463       R -> K (in dbSNP:rs3907239).
FT                                /FTId=VAR_039329.
SQ   SEQUENCE   555 AA;  62581 MW;  06528F9519CE211E CRC64;
     MPTTVDDVLE HGGEFHFFQK QMFFLLALLS ATFAPIYVGI VFLGFTPDHR CRSPGVAELS
     LRCGWSPAEE LNYTVPGPGP AGEASPRQCR RYEVDWNQST FDCVDPLASL DTNRSRLPLG
     PCRDGWVYET PGSSIVTEFN LVCANSWMLD LFQSSVNVGF FIGSMSIGYI ADRFGRKLCL
     LTTVLINAAA GVLMAISPTY TWMLIFRLIQ GLVSKAGWLI GYILITEFVG RRYRRTVGIF
     YQVAYTVGLL VLAGVAYALP HWRWLQFTVS LPNFFFLLYY WCIPESPRWL ISQNKNAEAM
     RIIKHIAKKN GKSLPASLQR LRLEEETGKK LNPSFLDLVR TPQIRKHTMI LMYNWFTSSV
     LYQGLIMHMG LAGDNIYLDF FYSALVEFPA AFMIILTIDR IGRRYPWAAS NMVAGAACLA
     SVFIPGDLQW LKIIISCLGR MGITMAYEIV CLVNAELYPT FIRNLGVHIC SSMCDIGGII
     TPFLVYRLTN IWLELPLMVF GVLGLVAGGL VLLLPETKGK ALPETIEEAE NMQRPRKNKE
     KMIYLQVQKL DIPLN
//
